Surmodics, Inc. Forecasted to Post FY2026 Earnings of $0.87 Per Share (NASDAQ:SRDX)

Surmodics, Inc. (NASDAQ:SRDX) – Investment analysts at Barrington Research cut their FY2026 earnings per share estimates for Surmodics in a research note issued on Thursday, August 1st. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of $0.87 for the year, down from their previous estimate of $0.88. Barrington Research has a “Market Perform” rating on the stock. The consensus estimate for Surmodics’ current full-year earnings is ($0.51) per share.

Other analysts have also issued research reports about the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Monday. StockNews.com began coverage on Surmodics in a research report on Saturday. They set a “hold” rating on the stock. Sidoti reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Surmodics in a report on Wednesday, May 29th. Finally, Lake Street Capital reiterated a “hold” rating and set a $43.00 price target on shares of Surmodics in a research report on Wednesday, May 29th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

Shares of NASDAQ SRDX opened at $41.25 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.59. The stock has a market capitalization of $588.64 million, a price-to-earnings ratio of 43.42 and a beta of 1.18. The firm’s 50 day simple moving average is $41.86 and its 200-day simple moving average is $34.62. Surmodics has a 12 month low of $25.17 and a 12 month high of $42.44.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in Surmodics during the 4th quarter worth approximately $163,000. Hillsdale Investment Management Inc. raised its stake in Surmodics by 15.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares during the last quarter. Lazard Asset Management LLC raised its stake in Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after purchasing an additional 673 shares during the last quarter. Bailard Inc. acquired a new stake in Surmodics during the 2nd quarter worth $257,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Surmodics by 7.5% during the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after buying an additional 481 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).